UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
UNITED THERAPEUTICS Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$543.15+10.03 (+1.88%)
Close on Oct 19, 2026
- Market cap
- $24.88B
- P/E (TTM)
- 19.4
- Dividend yield
- –
UNITED THERAPEUTICS Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Tyvaso | $1.88B | $1.62B | $1.23B | $873.00M | $607.50M | $483.30M | $415.60M | $415.20M | $372.90M | $404.60M | 59.0% | +15.9% |
| Tyvaso DPI | $1.29B | $1.03B | $731.10M | $158.30M | $0 | – | – | – | – | – | 40.6% | +25.0% |
| Nebulized Tyvaso | $585.70M | $586.80M | $502.60M | $714.70M | $607.50M | – | – | – | – | – | 18.4% | -0.2% |
| Remodulin | $526.80M | $538.10M | $494.80M | $500.20M | $513.70M | $516.70M | $587.00M | $599.00M | $670.90M | $602.30M | 16.6% | -2.1% |
| Orenitram | $496.90M | $434.30M | $359.40M | $325.10M | $306.10M | $293.10M | $225.30M | $205.10M | $185.80M | $157.20M | 15.6% | +14.4% |
| Unituxin | $226.80M | $238.70M | $198.90M | $182.90M | $202.30M | $122.90M | $113.70M | $84.80M | $76.00M | $62.50M | 7.1% | -5.0% |
| Adcirca | $30.00M | $23.80M | $28.90M | $41.30M | $55.90M | $67.30M | $107.20M | $323.70M | $419.70M | $372.20M | 0.9% | +26.1% |
| Other | $24.00M | $22.10M | $11.80M | $13.80M | $0 | $0 | – | – | – | – | 0.8% | +8.6% |
| Net product sales | – | – | – | – | – | $1.48B | $1.45B | $1.63B | $1.73B | $1.60B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $3.04B | $2.74B | $2.20B | $1.81B | $1.56B | $1.41B | $1.32B | $1.53B | $1.54B | $1.46B | 95.4% | +10.9% |
| ROW | $145.70M | $137.70M | $125.30M | $122.20M | $121.30M | $71.20M | $125.60M | – | – | – | 4.6% | +5.8% |
| Rest of World | – | – | – | – | – | $71.20M | $125.60M | $99.60M | $188.50M | $136.90M | – | – |
From the segment and revenue-disaggregation notes of United Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.